SEC Form 4 · accession 0000899243-17-017898

AILERON THERAPEUTICS INC · ALRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jul 5, 2017

Accepted (ET)

Jul 5, 2017 · 8:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001420565

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 5, 2017	C	90,218	—	A	90,318	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series C-2 Preferred Stock^F1	—	Jul 5, 2017	C	211,930	D	—	—	Common Stock	21,327	D
Series D Preferred Stock^F1	—	Jul 5, 2017	C	127,158	D	—	—	Common Stock	12,796	D
Series E Preferred Stock^F1	—	Jul 5, 2017	C	298,500	D	—	—	Common Stock	30,039	D
Series E-1 Preferred Stock^F1	—	Jul 5, 2017	C	258,912	D	—	—	Common Stock	26,055	D

F1The Series C-2, Series D, Series E and Series E-1 Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C-2, Series D, Series E and Series E-1 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.